<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785421</url>
  </required_header>
  <id_info>
    <org_study_id>CONKO 004</org_study_id>
    <secondary_id>CCT-NAPN-16752</secondary_id>
    <nct_id>NCT00785421</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Enoxaparin in Pancreatic Cancer</brief_title>
  <acronym>PROSPECT</acronym>
  <official_title>A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CONKO-Studiengruppe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CONKO-Studiengruppe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is
      powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the
      experimental arm.

      N=540pts, dropout-rate 15%, power 80 %, two sided, significant level 5%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% of patients (pts) diagnosed with pancreatic adenocarcinoma (PA) develop
      venous thromboembolism, which may contribute to the dismal prognosis of PA. A small phase II
      trial suggested an improved survival by the addition of low molecular weight heparin (LMWH)
      to chemotherapy. We conducted a small pilot study which indicated that the addition of
      enoxaparin to chemotherapy GFFC chemotherapy is safe and feasible in pts with advanced PA.
      Furthermore, results of several phase III studies suggest that pts in good performance status
      may benefit from more intensive chemotherapy regimen (Riess et al; Heinemann et al; ASCO
      2005). Based on these considerations we started the multicenter phase III study CONKO 004.

      540 patients are to be recruited into this study. Primary stratification takes place
      according to Karnofsky performance status and kidney function. Patients with KPS &gt; 80% and
      normal kidney function receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2
      (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/-
      Enoxaparin 1mg/kg daily s.c.). Pts with KPS &lt; 80 % and increased creatinin plasma levels
      (&gt;1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15;
      q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all
      patients who have not progressed received the standard therapy (gemcitabine mono) +/-
      Enoxaparin 40mg/d s.c.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DVT/TVE event rate</measure>
    <time_frame>After 12 events and after 24 events or after 540 pts recruited</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTP, OS, side effects</measure>
    <time_frame>after 12 events and after 24 events or after 540 pts are recruited</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with KPS &gt; 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).
Pts with KPS &lt; 80 % and increased creatinin plasma levels (&gt;1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.
After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with KPS &gt; 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).
Pts with KPS &lt; 80 % and increased creatinin plasma levels (&gt;1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.
After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS &lt; 80 % and increased creatinin plasma levels (&gt;1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>gemcitabine</other_name>
    <other_name>cisplatin</other_name>
    <other_name>folinic acid</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy with LMWH - enoxaparin</intervention_name>
    <description>1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>gemcitabine</other_name>
    <other_name>cisplatin</other_name>
    <other_name>folinic acid</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>only chemotherapy</intervention_name>
    <description>observation, no treatment with LMWH</description>
    <arm_group_label>B</arm_group_label>
    <other_name>gemcitabin</other_name>
    <other_name>cisplatin</other_name>
    <other_name>folinic acid</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological or cytological pancreatic carcinoma, stage IV A, b

          -  no preceding radio or chemotherapy of the primarius or the reference lesions

          -  Karnofsky performance status ≥ 60%

          -  measurable tumor lesion by spiral CT or MRT not older than 14 days

          -  no deep venous thrombosis within the last 2 years

          -  patient compliance and geographical proximity of the residence, which make an adequate
             follow up possible

          -  sufficient bone marrow reserve: leukocyte ≥ 3.5 × 109 /l, thrombocyte ≥ 100 × 109 /l

          -  signed informed consent

          -  minimum age of 18 years

          -  women/men must provide sufficient pregnancy prevention

        Exclusion Criteria:

          -  preexisting indication for anti-coagulation of other reason

          -  bleeding in the last 2 weeks or increased bleeding risk (e.g. serious coagulating
             disturbance, active stomach or intestine ulzera, or had operational interferences in
             the last 2 weeks)

          -  body weight &lt; 45 kg and/or &gt; 100 kg

          -  pregnancy or insufficient preventing methods in the study process

          -  serious illness, which are incompatible with a study participation

          -  hypersensitivity to study drugs

          -  patients with serious kidney malfunction (Creatininclearance &lt; 30 ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanno Riess, PHD</last_name>
    <role>Study Director</role>
    <affiliation>CONKO Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin - Berlin - Charite</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.conko-studien.de</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CONKO-Studiengruppe</investigator_affiliation>
    <investigator_full_name>Uwe Pelzer MD</investigator_full_name>
    <investigator_title>Dr. med. Uwe Pelzer</investigator_title>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>LMWH</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

